Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

Launched by JONSSON COMPREHENSIVE CANCER CENTER · Feb 18, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to use magnetic resonance imaging (MRI) combined with artificial intelligence (AI) to improve the diagnosis of prostate cancer. The goal is to enhance the quality of MRI images and the information they provide, which may help doctors better classify prostate cancer with less invasive methods than those currently available. By participating in this study, men who have a suspicion of prostate cancer or have already had a biopsy confirming it could contribute to advancing future prostate cancer diagnosis techniques.

To be eligible for this trial, participants need to be male, 18 years or older, and must have either a clinical suspicion of prostate cancer or a confirmed diagnosis through biopsy. They also need to have had or be scheduled for a specific type of MRI at the University of California at Los Angeles (UCLA). It’s important to note that individuals with certain medical devices, severe claustrophobia, or prior treatments like radiotherapy may not qualify for the study. Participants can expect to undergo advanced MRI scans that could lead to better diagnostic methods in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male patients 18 years of age and older
• • Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
• • Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
• • Ability to provide consent
• Exclusion Criteria:
• • Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)
• • Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
• • Prior radiotherapy